acne scar acne scar
Conditions
Interventions
Adipose tissue will be harvested from the abdominal area via liposuction under local tumescent anesthesia using a vacuum-assisted technique. The collected fat will then be processed in an ISO Class 5
Experimental Device
adipose-derived stem cells (ADSCs) injection
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Participants aged 18 to 60 years old 2. Participants with superficial or deep boxcar acne scars on the face for at least 3 months 3. Participants able to comply with study procedures and attend all scheduled follow-up visits 4. Participants with Fitzpatrick skin types III to V 5. Presence of fine periocular wrinkles 6. No history of photosensitive dermatoses, skin cancer, keloid formation, or immunodeficiency. 7. No other acne-scar treatment within the past 6 months. 8. Sufficient abdominal subcutaneous fat as assessed by the dermatologic surgeon.
Exclusion criteria
Exclusion criteria: 1. Participants with photosensitive dermatoses, history of skin cancer, keloid formation, immunodeficiency, or active skin infection/inflammation at the treatment site. 2. Regular smokers. 3. Pregnant, postpartum (<3 months), or breastfeeding participants. 4. Participants unable to comply with treatment or follow-up schedules. 5. Participants who have used topical agents for acne-scar treatment (e.g., alpha-hydroxy acids or retinoic acid) on the treatment area within 6 months prior to enrollment. 6. Participants who have received laser or radiofrequency treatments on the target area within 3 months prior to enrollment. 7. Participants who have used systemic corticosteroids or other immunosuppressive drugs within 6 months prior to enrollment. 8. Participants who have taken isotretinoin within 12 months prior to enrollment. 9. Participants who did not provide written informed consent to participate. 10. Participants with any condition deemed unsafe for study participation by the investigator. 11. Participants with known allergy to local anesthetics containing xylocaine or epinephrine. 12. Participants with uncontrolled hypertension or pheochromocytoma (contraindications to epinephrine-containing anesthetics). 13. Participants currently taking anticoagulant medications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acne scar volume Baseline, 1 month after 1st injection, 1, 3, 6, 9 and 12 months after 2nd injection Antera 3D,Texture Baseline, 1 month after 1st injection, 1, 3, 6, 9 and 12 months after 2nd injection Antera 3D,Physician assessments 1 month after 1st injection, 1, 3, 6, 9 and 12 months after 2nd injection Quartile scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Participants improvement scale 1 month after 1st injection, 1, 3, 6, 9 and 12 months after 2nd injection Quartile scale,Pain score During treatment Visual analog scale,Safety 1 month after 1st injection, 1, 3, 6, 9 and 12 months after 2nd injection Adverse events,skin firmness/elasticity Baseline, 1 month after 1st injection, 1, 3, 6, 9 and 12 months after 2nd injection Cutometer,Hydration Baseline, 1 month after 1st injection, 1, 3, 6, 9 and 12 months after 2nd injection Corneometer | — |
Countries
Thailand
Contacts
Public ContactRungsima Wanitphakdeedecha
Department of Dermatology, Faculty of medicine Siriraj hospital, Mahidol university
Outcome results
None listed